MIRANCMHealthcare·Drug Manufacturers - General#19 in industry

MIRA Pharmaceuticals, Inc.

-23.9% · 90d

$1.02

-0.03 (-2.86%)

After-Hours $1.02(+0.00)

News

No News Yet

Press releases and SEC filings for MIRA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$42.9M

Open$1.00

Prev Close$1.05

Day Range$1.00 – $1.05

52W Range$0.90 – $2.45

Volume107,973

P/E (TTM)—

EPS$-1.35

Dividend Yield—

Beta1.94

About

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Healthcare · Drug Manufacturers - General

mirapharmaceuticals.com